Shares of Peregrine Pharmaceuticals Inc. (PPHM) are losing about 76.0 percent on Monday after it revealed discrepancies in data from a phase II study of its lead drug candidate bavituximab in non-small cell lung cancer.
Peregrine, while preparing for an end-of-phase II meeting with regulatory authorities and following recent data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments.
According to the company, a review of information has found that the source of the discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.
Earlier this month, Peregrine reported positive results for bavituximab in a Phase IIb trial in non-small cell lung cancer, as the drug showed a statistically significant improvement in overall survival and a doubling of median overall survival. The company now says investors should not rely on clinical data it earlier provided with regard to Phase II bavituximab trial for second-line non-small cell lung cancer.
The company in March too had revealed data discrepancies, after an independent review showed unexpectedly high progression-free survival rates in lung cancer patients receiving standard chemotherapy.
Bavituximab is a genetically engineered antibody, designed to target a lipid molecule found on tumor blood vessels, and works by suppressing the immune system. It is being studied as a treatment for a range of cancers, including pancreatic and breast cancer. Peregrine said the discrepancy will have no impact on other ongoing bavituximab trials.
Shares of Peregrine are trading at $1.26, down $4.12 or 76.57%, on a volume of over 56.0 million shares on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.